Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 287

1.

The use of real-world data in cancer drug development.

Skovlund E, Leufkens HGM, Smyth JF.

Eur J Cancer. 2018 Sep;101:69-76. doi: 10.1016/j.ejca.2018.06.036. Epub 2018 Jul 18.

PMID:
30031168
2.

Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies.

Rajan A, Berns A, Ringborg U, Celis J, Ponder B, Caldas C, Livingston D, Bristow RG, Hecht TT, Tursz T, van Luenen H, Bono P, Helander T, Seamon K, Smyth JF, Louvard D, Eggermont A, van Harten WH.

Mol Oncol. 2016 May;10(5):645-51. doi: 10.1016/j.molonc.2015.12.007. Epub 2015 Dec 23. Review.

3.

Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?

Bergmann L, Enzmann H, Broich K, Hebborn A, Marsoni S, Goh L, Smyth JF, Zwierzina H.

Ann Oncol. 2014 Feb;25(2):303-6. doi: 10.1093/annonc/mdt488. Epub 2013 Dec 10. No abstract available.

PMID:
24335759
4.

Association of galectin-3 expression with melanoma progression and prognosis.

Brown ER, Doig T, Anderson N, Brenn T, Doherty V, Xu Y, Bartlett JM, Smyth JF, Melton DW.

Eur J Cancer. 2012 Apr;48(6):865-74. doi: 10.1016/j.ejca.2011.09.003. Epub 2011 Nov 7.

PMID:
22071132
5.

A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.

Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L; Australian Ovarian Cancer Study Group, Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR.

Cancer Res. 2012 Jan 1;72(1):66-75. doi: 10.1158/0008-5472.CAN-11-2178. Epub 2011 Nov 7.

6.

Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy.

Storey DJ, McLaren DB, Atkinson MA, Butcher I, Frew LC, Smyth JF, Sharpe M.

Ann Oncol. 2012 Jun;23(6):1542-9. doi: 10.1093/annonc/mdr447. Epub 2011 Oct 17.

PMID:
22007078
7.

The interface between medical oncology and supportive and palliative cancer care.

Storey DJ, Fallon MT, Smyth JF.

Semin Oncol. 2011 Jun;38(3):337-42. doi: 10.1053/j.seminoncol.2011.03.021.

PMID:
21600360
8.

Clinically relevant fatigue in recurrence-free prostate cancer survivors.

Storey DJ, McLaren DB, Atkinson MA, Butcher I, Liggatt S, O'Dea R, Smyth JF, Sharpe M.

Ann Oncol. 2012 Jan;23(1):65-72. doi: 10.1093/annonc/mdr034. Epub 2011 Mar 24.

PMID:
21436185
9.

Higher incidence of isolated brain metastases in ovarian cancer patients with previous early breast cancer.

Faluyi OO, Gourley C, Smyth JF, Faratian D, Williams AR, Rye T, Rye R, Stewart M, Mackean MJ.

Int J Gynecol Cancer. 2010 Dec;20(9):1511-7.

PMID:
21370594
10.

WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis.

Paige AJ, Zucknick M, Janczar S, Paul J, Mein CA, Taylor KJ, Stewart M, Gourley C, Richardson S, Perren T, Ganesan TS, Smyth JF, Brown R, Gabra H.

Eur J Cancer. 2010 Mar;46(4):818-25. doi: 10.1016/j.ejca.2009.12.021. Epub 2010 Jan 13.

PMID:
20074932
11.

The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.

Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T.

J Clin Invest. 2009 Oct;119(10):3011-23. doi: 10.1172/JCI39065. Epub 2009 Sep 8.

12.

WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3.

Gourley C, Paige AJ, Taylor KJ, Ward C, Kuske B, Zhang J, Sun M, Janczar S, Harrison DJ, Muir M, Smyth JF, Gabra H.

Cancer Res. 2009 Jun 1;69(11):4835-42. doi: 10.1158/0008-5472.CAN-08-2974. Epub 2009 May 19.

13.

What to do after winning the Nobel Prize--work harder!

Smyth JF.

Eur J Cancer. 2009 Feb;45(3):318. doi: 10.1016/j.ejca.2008.11.025. Epub 2009 Jan 2. No abstract available.

PMID:
19121934
14.

Hormone therapy for epithelial ovarian cancer.

Langdon SP, Smyth JF.

Curr Opin Oncol. 2008 Sep;20(5):548-53. doi: 10.1097/CCO.0b013e3283063912. Review.

PMID:
19106659
15.

Communication as important as cure.

Smyth JF.

Eur J Cancer. 2009 Jan;45(1):6-7. doi: 10.1016/j.ejca.2008.08.022. Epub 2008 Nov 29. No abstract available.

PMID:
19042122
16.

Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.

Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF.

Clin Cancer Res. 2008 May 15;14(10):3105-12. doi: 10.1158/1078-0432.CCR-07-1652.

17.

Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.

Storey DJ, Rush R, Stewart M, Rye T, Al-Nafussi A, Williams AR, Smyth JF, Gabra H.

Cancer. 2008 May 15;112(10):2211-20. doi: 10.1002/cncr.23438.

18.

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.

Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR, Smyth JF.

Ann Oncol. 2008 Jul;19(7):1340-6. doi: 10.1093/annonc/mdn054. Epub 2008 Mar 5.

PMID:
18325912
19.

The strength of European oncology.

Smyth JF.

Eur J Cancer. 2008 Jan;44(1):6-7. No abstract available.

PMID:
18077154
20.

Validation of a new prognostic index for advanced epithelial ovarian cancer: results from its application to a UK-based cohort.

Clark TG, Stewart M, Rye T, Smyth JF, Gourley C.

J Clin Oncol. 2007 Dec 10;25(35):5669-70; author reply 5670-1. No abstract available.

PMID:
18065745
21.

Disclosing gaps between supportive and palliative care: the past 20 years.

Smyth JF.

Support Care Cancer. 2008 Feb;16(2):109-11. Epub 2007 Nov 10. No abstract available.

PMID:
17994254
22.

Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.

Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP.

Gynecol Oncol. 2007 Sep;106(3):461-8. Epub 2007 Jul 10.

PMID:
17624412
23.

Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.

Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR, Nafussi AA, Rye T, Rye R, Stewart M, McCurdy J, Mano M, Reed N, McMahon T, Vasey P, Gabra H, Langdon SP.

Clin Cancer Res. 2007 Jun 15;13(12):3617-22.

24.

Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer.

Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP.

Clin Cancer Res. 2007 Mar 1;13(5):1438-44.

25.

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling.

Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP.

Mol Cancer Ther. 2007 Jan;6(1):93-100.

26.

Food for thought - should we stop doing research?

Smyth JF.

Eur J Cancer. 2007 Jan;43(1):6-7. Epub 2006 Nov 14. No abstract available.

PMID:
17107781
27.

Creating a unified Europe: losing identity and visibility for a greater profit?

Smyth JF.

Nat Clin Pract Oncol. 2006 Apr;3(4):169. No abstract available.

PMID:
16596124
28.

Integrative oncology--what's in a name?

Smyth JF.

Eur J Cancer. 2006 Mar;42(5):572-3. Epub 2006 Feb 3. No abstract available.

PMID:
16459074
29.

An irresistible thirst for knowledge!

Smyth JF.

Eur J Cancer. 2006 Mar;42(4):432-3. Epub 2006 Feb 7. No abstract available.

PMID:
16455239
30.

Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells.

McPhillips F, Mullen P, MacLeod KG, Sewell JM, Monia BP, Cameron DA, Smyth JF, Langdon SP.

Carcinogenesis. 2006 Apr;27(4):729-39. Epub 2005 Dec 6.

PMID:
16332724
31.

Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen.

O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon SP.

Endocr Relat Cancer. 2005 Dec;12(4):851-66.

PMID:
16322326
32.

Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.

Mullen P, McPhillips F, Monia BP, Smyth JF, Langdon SP.

Int J Cancer. 2006 Mar 15;118(6):1565-71.

33.

The IgLON family in epithelial ovarian cancer: expression profiles and clinicopathologic correlates.

Ntougkos E, Rush R, Scott D, Frankenberg T, Gabra H, Smyth JF, Sellar GC.

Clin Cancer Res. 2005 Aug 15;11(16):5764-8.

34.

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.

Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, Smyth JF, Langdon SP.

Cancer Res. 2005 Aug 1;65(15):6789-800.

35.

The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines.

Sewell JM, Mayer I, Langdon SP, Smyth JF, Jodrell DI, Guichard SM.

Eur J Cancer. 2005 Jul;41(11):1637-44.

PMID:
15953713
36.

WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear.

Gourley C, Paige AJW, Taylor KJ, Scott D, Francis NJ, Rush R, Aldaz CM, Smyth JF, Gabra H.

Int J Oncol. 2005 Jun;26(6):1681-1689.

37.

Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migration.

Sewell JM, Smyth JF, Langdon SP.

Exp Cell Res. 2005 Mar 10;304(1):305-16. Epub 2004 Dec 9.

PMID:
15707595
38.

Risk factors for prolonged disability after whiplash injury: a prospective study.

Gun RT, Osti OL, O'Riordan A, Mpelasoka F, Eckerwall CG, Smyth JF.

Spine (Phila Pa 1976). 2005 Feb 15;30(4):386-91.

PMID:
15706334
39.

Phase II study of E7070 in patients with metastatic melanoma.

Smyth JF, Aamdal S, Awada A, Dittrich C, Caponigro F, Schöffski P, Gore M, Lesimple T, Djurasinovic N, Baron B, Ravic M, Fumoleau P, Punt CJ; EORTC New Drug Development and Melanoma Groups.

Ann Oncol. 2005 Jan;16(1):158-61.

PMID:
15598954
40.
41.
42.

Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression.

Stronach EA, Sellar GC, Blenkiron C, Rabiasz GJ, Taylor KJ, Miller EP, Massie CE, Al-Nafussi A, Smyth JF, Porteous DJ, Gabra H.

Cancer Res. 2003 Dec 15;63(24):8648-55.

43.

'Onco-tourism'-season ticket, anyone?

Smyth JF.

Eur J Cancer. 2004 Jan;40(1):7. No abstract available.

PMID:
14687782
44.

Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.

Cummings J, Ethell BT, Jardine L, Boyd G, Macpherson JS, Burchell B, Smyth JF, Jodrell DI.

Cancer Res. 2003 Dec 1;63(23):8443-50.

45.

Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.

Cummings J, Zelcer N, Allen JD, Yao D, Boyd G, Maliepaard M, Friedberg TH, Smyth JF, Jodrell DI.

Biochem Pharmacol. 2004 Jan 1;67(1):31-9.

PMID:
14667926
46.

Rationale for drug combinations.

Smyth JF.

Eur J Cancer. 2003 Sep;39(13):1816-7. No abstract available.

PMID:
12932657
47.
48.

OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer.

Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B, Scott D, Brown I, Williams AR, Bates PA, Smyth JF, Gabra H.

Nat Genet. 2003 Jul;34(3):337-43.

PMID:
12819783
49.

The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo.

Wall L, Burke F, Smyth JF, Balkwill F.

Gynecol Oncol. 2003 Jan;88(1 Pt 2):S149-51. Review. No abstract available.

PMID:
12586108
50.

Neuregulin expression, function, and signaling in human ovarian cancer cells.

Gilmour LM, Macleod KG, McCaig A, Sewell JM, Gullick WJ, Smyth JF, Langdon SP.

Clin Cancer Res. 2002 Dec;8(12):3933-42.

Supplemental Content

Loading ...
Support Center